ArticleFrontiers in endocrinology2026
Optimizing estradiol duration to reduce progesterone-related cancellation in hormone replacement therapy frozen embryo transfer cycles: toward a patient-tailored approach.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study whether the duration of estradiol exposure in hormone replacement therapy (HRT) cycles for frozen embryo transfer (FET) is associated with progesterone-related cycle cancellation and reproductive outcomes. Materials and methods: This retrospective cohort study included 2, 001 HRT-FET cycles following a freeze-all strategy performed between January 2020 and June 2025. Patients were stratified according to estradiol exposure duration into short (8-9 days; n = 980), intermediate (10-11 days; n = 746), and prolonged (12-14 days; n = 275) exposure groups. Serum progesterone levels were assessed on the day of progesterone initiation. The primary outcome was cycle cancellation due to progesterone elevation (progesterone ≥1.5 ng/mL on the day of progesterone initiation). Secondary outcomes included implantation, clinical pregnancy, miscarriage, and live birth rates. Results: The overall cycle cancellation rate was 3.3% (66/2, 001) and increased significantly with longer estradiol exposure, occurring in 2.1%, 3.9%, and 5.8% of cycles in the short, intermediate, and prolonged groups, respectively (OR 1.69 per category, 95% CI 1.22-2.34, p = 0.002). Live birth rates per transfer were similar across groups (47.2%, 52.3%, and 49.4%, respectively; p = 0.122). In multivariable analysis, prolonged estradiol exposure (OR 3.68, 95% CI 1.76-7.71, p < 0.001), intermediate exposure (OR 2.08, 95% CI 1.13-3.81, p = 0.019), age >37 years (OR 2.58, 95% CI 1.36-4.90, p = 0.004), and diminished ovarian reserve (OR 5.13, 95% CI 2.87-9.16, p < 0.001) were independent predictors of cycle cancellation, whereas polycystic ovary syndrome (OR 0.23, 95% CI 0.08-0.69, p = 0.009) was independently associated with a lower likelihood of cancellation. In the multivariable model restricted to transferred cycles, neither intermediate nor prolonged estradiol exposure was independently associated with live birth compared with short estradiol exposure (intermediate: OR 1.25, 95% CI 0.88-1.78, p = 0.204; prolonged: OR 0.93, 95% CI 0.57-1.51, p = 0.775). Conclusions: Prolonged estradiol exposure in HRT-FET cycles is associated with increased progesterone-related cycle cancellation without improving reproductive outcomes. A patient-tailored approach based on ovarian reserve status and age may help reduce avoidable cancellations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.